Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Novelix Pharmaceuticals live price: ₹55.1. It opened at ₹58 vs previous close ₹57; intraday high/low: ₹58/₹54. The 50 & 200 DMA stand at ₹56.37/₹49.48.

Novelix Pharmaceuticals Performance

  • Today's Low
  • ₹54
  • Today's High
  • ₹58
  • 52 Week Low
  • ₹27
  • 52 Week High
  • ₹70
  • Open Price₹58
  • Previous Close₹57
  • Volume2,562
  • 50 DMA₹56.37
  • 100 DMA₹55.43
  • 200 DMA₹49.48

Novelix Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 2.61%
  • Over 3 Month + 0.62%
  • Over 6 Month + 16.27%
  • Over 1 Year + 107.07%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.1
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 97
  • P/B Ratio
  • 3.3
  • Average True Range
  • 5.08
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.28
  • RSI
  • 48.43
  • MFI
  • 31.21

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹55.10
-1.44 (-2.55%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹55.69
  • 50 Day
  • ₹56.37
  • 100 Day
  • ₹55.43
  • 200 Day
  • ₹49.48

Resistance and Support

55.72 Pivot Speed
  • R3 60.98
  • R2 59.43
  • R1 57.27
  • S1 53.56
  • S2 52.01
  • S3 49.85

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 127.97 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 78 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

49.43%
46.42%
4.15%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹55 As on 23 April, 2026 | 07:02

The Market Cap of Novelix Pharmaceuticals is ₹97.1 Cr As on 23 April, 2026 | 07:02

The P/E ratio of Novelix Pharmaceuticals is 53.1 As on 23 April, 2026 | 07:02

The PB ratio of Novelix Pharmaceuticals is 3.3 As on 23 April, 2026 | 07:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23